pozanicline

Also Known As:

2-methyl-3-(2-pyrrolidinylmethoxy)pyridine dihydrochloride, (R)-isomer; 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine dihydrochloride, (S)-isomer; 2-methyl-3-(2-pyrrolidinylmethoxy)pyridine, (S)-isomer; ABT 089; ABT-089

Networked: 12 relevant articles (5 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - pozanicline: 12
  - Pyridines: 88
    - pozanicline: 12

Experts

1.	Saltarelli, Mario D: 4 articles (07/2015 - 01/2011)
2.	Abi-Saab, Walid M: 3 articles (07/2015 - 01/2011)
3.	Decker, Michael W: 3 articles (04/2014 - 01/2004)
4.	Apostol, George: 3 articles (06/2012 - 01/2011)
5.	Robieson, Weining Z: 3 articles (06/2012 - 01/2011)
6.	Wilens, Timothy E: 3 articles (01/2011 - 06/2006)
7.	Pritchett, Yili L: 2 articles (07/2015 - 02/2012)
8.	Childress, Ann: 2 articles (11/2014 - 01/2011)
9.	Bordia, Tanuja: 2 articles (10/2014 - 04/2014)
10.	Quik, Maryka: 2 articles (10/2014 - 04/2014)

Related Diseases

1.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 11/01/2014 - "Pozanicline was shown to be effective in a pilot study in humans with ADHD, but larger trials were negative. " 06/01/2006 - "Data from this pilot study suggest that ABT-089 might be effective in treating adult ADHD and that it is well tolerated. " 01/01/2011 - "Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials." 02/01/2012 - "This study examined the efficacy and safety of the α(4)β(2) NNR partial agonist ABT-089 versus placebo in adults with ADHD. " 01/01/2011 - "There was no statistically significant difference between ABT-089 and placebo in mean change from baseline to final evaluation of ADHD-RS-IV (HV) Total Score or other outcome measures at any dose in either study. "
2.	Alzheimer Disease (Alzheimer's Disease) 07/01/2015 - "Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease." 07/01/2015 - "When administered as adjunctive therapy to acetylcholinesterase inhibitors, ABT-089 was not efficacious in mild to moderate Alzheimer disease. " 07/01/2015 - "ABT-089, an α4β2 neuronal nicotinic receptor partial agonist, was evaluated for efficacy and safety in mild to moderate Alzheimer disease patients receiving stable doses of acetylcholinesterase inhibitors. "
3.	Dyskinesias (Dyskinesia) 04/01/2014 - "ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease." 10/01/2014 - "The general nAChR agonist nicotine, as well as several nAChR agonists (varenicline, ABT-089 and ABT-894), reduces l-dopa-induced abnormal involuntary movements or dyskinesias up to 60% in parkinsonian nonhuman primates and rodents. "
4.	Cognitive Dysfunction 01/01/2004 - "Together these data suggest that ABT-089 is a NNR modulator with the potential for treating cognitive disorders with markedly limited adverse cardiovascular and gastrointestinal side effects." 01/01/2004 - "ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders."
5.	Vomiting 10/15/2007 - "Notably, tolerability issues that might be expected of a nAChR agonist, such as nausea and emesis, were not observed at efficacious doses of ABT-089. "

Related Drugs and Biologics

1.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
2.	pozanicline
3.	Levodopa (L Dopa)
4.	Measles-Mumps-Rubella Vaccine (MMR Vaccine)
5.	Succinic Acid (Succinate)
6.	Fenretinide
7.	Paclitaxel (Taxol)
8.	Vaccines
9.	Etidronic Acid (HEDP)
10.	Sarcosine (Methylglycine)

Related Therapies and Procedures

1.	Therapeutics